Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bayer Ag ADR (OP:BAYRY)

10.71 +0.01 (+0.13%)
Streaming Delayed Price Updated: 10:26 AM EDT, Apr 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bayer Ag ADR

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Best 4 Agriculture Companies For Your 2024 Investment Portfolio ↗
Agriculture is and remains, a crucial sector for sustaining life, offering investors diverse opportunities in this vital industry. 
Via Talk Markets
News headline image
Legal Victory For Bayer: Roundup Lawsuit Ends Five-Trial Losing Streak ↗
In a significant turn of events, Bayer AG (OTC: BAYRY) (OTC: BAYZF) emerged victorious in a California lawsuit filed by Bruce Jones, who alleged that the use of Roundup caused his non-Hodgkin... 
Via Benzinga
Topics Lawsuit
News headline image
ESG Stocks Take Center Stage As Damages From Climate-Related Events Rise Exponentially Within US ↗
With climate change becoming a mega market force, ESG investing is rising. The XVV is up 28% YTD. Agri-Tech stocks like Bayer AG, FMC Corporation, and Corteva Inc are providing climate resilience... 
Via Benzinga
Topics Climate Change
News headline image
AI Meets Biotech: 3 Top Stocks Transforming Medical Science ↗
The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
Bayer Faces $3.5M Verdict in Fifth Consecutive Roundup Weedkiller Loss ↗
Bayer AG (OTC: BAYRY) (OTC:  
Via Benzinga
News headline image
Bayer Faces Growing Pressure Amid Roundup Lawsuits as Philadelphia Trial Nears Conclusion ↗
The spotlight is on a Philadelphia trial as Bayer AG (OTC: BAYRY) (OTC: BAYZF) grapples with mounting legal challenges surrounding its Roundup weedkiller, prompted by multi-billion dollar verdicts  
Via Benzinga
Topics Lawsuit
News headline image
PFAS's Forever Problem: Ohio Lawsuit Against Chemical Companies Fizzles Out ↗
Big chemical companies won a lawsuit preventing 11.8 million Ohio residents from suing them for PFAS chemicals in their blood. 
Via Benzinga
Topics Lawsuit
News headline image
3 Battered Blue-Chip Stocks to Sell in December ↗
Steer clear of these once flourishing companies, each of which has problems they need to overcome before their share price rises again. 
Via InvestorPlace
News headline image
German Conglomerate Bayer Faces Investor Scrutiny Amid Unexpected Legal, Trial Setbacks ↗
Bayer AG (OTC: BAYRY) (OTC: BAYZF) reportedly held an investor call to address concerns after intense scrutiny from investors following a series of unforeseen setbacks, prompting questions about... 
Via Benzinga
News headline image
Analyst Assess Implications of Bristol Myers' Investigational Blood Thinner Post Bayer Trial Setback Amid Shaken Investor Confidence ↗
Monday, Bayer AG (OTC: BAYRY) (OTC: BAYZF)  
Via Benzinga
News headline image
Bayer's Blood Thinner Study Stopped Early Due To Lack Of Efficacy: Details ↗
Bayer AG (OTC: BAYRY) (OTC: BAYZF)  
Via Benzinga
News headline image
Bayer's Legal Victory Against Merck: Delaware Court Rules In Company's Favor Regarding Talc Lawsuits ↗
The Delaware Supreme Court reportedly ruled in favor of Bayer AG (OTC: BAYRY) (OTC: BAYZF), stating that the company is not accountable for lawsuits associated with talc-based foot powder products... 
Via Benzinga
Topics Lawsuit
News headline image
Bayer CEO Resists Full Tri-Split, German Conglomerate Cuts Management Jobs In The Face Of Q3 Loss ↗
Bayer AG (OTC: BAYRY) (OTC: BAYZF) CEO Bill Anderson announced  
Via Benzinga
News headline image
Earnings Review: Bayer To Make Strategic Changes After Q3 Results ↗
The latest financial statements from Bayer Group show a year-over-year decline in several key areas, painting a stark picture of the company’s fiscal health. 
Via Talk Markets
News headline image
Legal Woes Mount for Bayer As Roundup Weed Killer-Related Cancer Cases Continue, Faces Third Trial Loss ↗
Bayer AG (OTC: BAYRY) (OTC:  
Via Benzinga
News headline image
Cathie Wood’s Stock Shuffle: 4 Names She’s Loving, 3 She’s Leaving ↗
Investors tend to closely watch which Cathie Wood stocks are bought and sold as she has history of generating big returns in her ETFs 
Via InvestorPlace
News headline image
AI To Revolutionize Clinical Trials And Diagnostics ↗
With the help of technology, the pharmaceutical industry is gaining new insights that are fueling the development of next generation of drugs while also speeding up clinical trials and improving... 
Via Benzinga
Topics Artificial Intelligence
News headline image
From Years to Months: How AI is Shaping the Landscape of Clinical Trials ↗
Pharmaceutical companies are harnessing artificial intelligence (AI) to speed up the traditionally arduous process of clinical trials, potentially saving both time and significant sums of money. These... 
Via Benzinga
Topics Artificial Intelligence
News headline image
FDA Panel Says Popular OTC Cold, Allergy Medicine Might Be Useless - Stocks To Watch ↗
According to FDA panel experts who reviewed the latest research on the long-questioned phenylephrine, a drug ingredient used in several leading decongestants used by millions of Americans looking for... 
Via Benzinga
News headline image
Hawaiian Electric Says Power Lines Not Responsible For Deadly Lahaina Fire, China Targets Stock Market Revival, FTC Pauses Legal Battle With Amgen's $28B Horizon Deal: Today's Top Stories ↗
Reuters 
Via Benzinga
News headline image
German Pharma Firm Bayer's New Parkinson's Treatment Shows Promise: What the Phase 1 Trial Reveals ↗
Boston Scientific Corporation (NYSE: BSX) released 12-month results from the pivotal ADVENT trial of the FARAPULSE Pulsed Field Ablation (PFA) System, a nonthermal treatment in which electric fields... 
Via Benzinga
News headline image
FDA Approves Regeneron Pharmaceuticals' Higher Dose Of Eylea For Age-Related Blindness ↗
The FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration (wAMD), diabetic macular edema (DME),  
Via Benzinga
News headline image
As Tiziana Life Sciences (NASDAQ: TLSA) Prepares For Phase 2 Trials, Have They Successfully Derisked Foralumab? ↗
Tiziana Life Sciences, Inc. 
Via Benzinga
News headline image
Regeneron Pharma Says Fewer Aflibercept Injections Maintains Vision, Anatomic Improvements In Diabetic Macular Edema ↗
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced the first presentation of two-year (96 weeks) results from the pivotal PHOTON trial of aflibercept 8 mg with 12- and 16-week dosing regimens,... 
Via Benzinga
News headline image
Phase 1 Results Are "Extraordinary," Says Chairman Of Scientific Advisory Board As Biomedical Company Preps Phase 2 Trial For MS Treatment ↗
Tiziana Life Sciences (NASDAQ: TSLA) has presented data from its clinical trial showing that five of its six patients with an advanced stage of multiple sclerosis (MS) have shown a reduction in... 
Via Benzinga
News headline image
AstraZeneca's Imfinzi/Imjudo Combo Shows Sustained Overall Survival Benefit At Four Years In Liver Cancer ↗
AstraZeneca Plc (NASDAQ: AZN) released updated results from the HIMALAYA Phase 3 trial evaluating Imfinzi (durvalumab) plus Imjudo (tremelimumab-actl) in unresectable hepatocellular carcinoma (HCC)... 
Via Benzinga
News headline image
Bayers Says Neuronal Stem Cell Therapy For Parkinson's Shows Encouraging Action In Early-Stage Study ↗
Bayer AG (OTC: BAYRY) (OTC: BAYZF) and its subsidiary BlueRock Therapeutics LP announced  
Via Benzinga
News headline image
Experimental Stem Cell Therapy For Parkinson's Shows Promise in Phase I Trial: Reuters ↗
 
Via Benzinga
News headline image
Regeneron Stock Crumbles After FDA Rejects Its Next Blockbuster Contender ↗
The FDA still needs to review its inspection of a third-party facility, Regeneron said late Tuesday. 
Via Investor's Business Daily
News headline image
Unmasking Q2 2023's Stars & Strugglers: Industry ETFs And Top Stock Standouts ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.